ATA9952002A - Verwendung eines antikörpers gerichtet gegen lewis-antigene - Google Patents

Verwendung eines antikörpers gerichtet gegen lewis-antigene

Info

Publication number
ATA9952002A
ATA9952002A AT0099502A AT9952002A ATA9952002A AT A9952002 A ATA9952002 A AT A9952002A AT 0099502 A AT0099502 A AT 0099502A AT 9952002 A AT9952002 A AT 9952002A AT A9952002 A ATA9952002 A AT A9952002A
Authority
AT
Austria
Prior art keywords
antigene
directed against
antibody directed
against lewis
lewis
Prior art date
Application number
AT0099502A
Other languages
English (en)
Other versions
AT413486B (de
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0099502A priority Critical patent/AT413486B/de
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Priority to CA002488885A priority patent/CA2488885A1/en
Priority to JP2004518630A priority patent/JP2006510578A/ja
Priority to US10/519,323 priority patent/US7527789B2/en
Priority to PCT/EP2003/006912 priority patent/WO2004005349A2/en
Priority to EP03762553A priority patent/EP1517922A2/de
Priority to AU2003258498A priority patent/AU2003258498A1/en
Publication of ATA9952002A publication Critical patent/ATA9952002A/de
Application granted granted Critical
Publication of AT413486B publication Critical patent/AT413486B/de
Priority to US12/391,226 priority patent/US20090181030A1/en
Priority to AU2010203050A priority patent/AU2010203050C1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0099502A 2002-07-03 2002-07-03 Verwendung eines antikörpers gerichtet gegen lewis-antigene AT413486B (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT0099502A AT413486B (de) 2002-07-03 2002-07-03 Verwendung eines antikörpers gerichtet gegen lewis-antigene
JP2004518630A JP2006510578A (ja) 2002-07-03 2003-06-30 腫瘍関連グリコシル化に対する抗体に基づく製剤の使用
US10/519,323 US7527789B2 (en) 2002-07-03 2003-06-30 Use of a preparation based on an antibody directed against a tumor-associated glycosylation
PCT/EP2003/006912 WO2004005349A2 (en) 2002-07-03 2003-06-30 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures
CA002488885A CA2488885A1 (en) 2002-07-03 2003-06-30 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures
EP03762553A EP1517922A2 (de) 2002-07-03 2003-06-30 Auf einem gegen eine tumorassoziierte glycosylierung wie lewis-strukturen gerichteten antikörper basierende herstellung
AU2003258498A AU2003258498A1 (en) 2002-07-03 2003-06-30 Preparation based on an antibody directed against a tumor-associated glycosylation such as Lewis structures
US12/391,226 US20090181030A1 (en) 2002-07-03 2009-02-23 Use of a preparation based on an antibody directed against a tumor-associated glycosylation
AU2010203050A AU2010203050C1 (en) 2002-07-03 2010-07-19 Preparation based on an antibody directed against a tumor-associated glycosylation such as Lewis structures

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0099502A AT413486B (de) 2002-07-03 2002-07-03 Verwendung eines antikörpers gerichtet gegen lewis-antigene

Publications (2)

Publication Number Publication Date
ATA9952002A true ATA9952002A (de) 2005-08-15
AT413486B AT413486B (de) 2006-03-15

Family

ID=30004242

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0099502A AT413486B (de) 2002-07-03 2002-07-03 Verwendung eines antikörpers gerichtet gegen lewis-antigene

Country Status (7)

Country Link
US (2) US7527789B2 (de)
EP (1) EP1517922A2 (de)
JP (1) JP2006510578A (de)
AT (1) AT413486B (de)
AU (2) AU2003258498A1 (de)
CA (1) CA2488885A1 (de)
WO (1) WO2004005349A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
US20080227736A1 (en) * 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
JP2017512759A (ja) * 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
GB201515094D0 (en) * 2015-08-25 2015-10-07 Univ Nottingham Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164489A (en) * 1988-05-23 1992-11-17 Board Of Regents, University Of Texas System Lung growth stimulatory and inhibitory factors for carcinoma tumor cells
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
EP0521692A3 (en) 1991-07-02 1993-02-03 The Biomembrane Institute Inhibition of tumor cell metastasis potential and invasiveness by chemically-defined oligosaccharides, their derivatives, mimetics and antibodies directed to them
ATE188708T1 (de) * 1991-08-21 2000-01-15 Novartis Ag Antikörperderivate
DE19531348A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
EP2112167A3 (de) 1999-06-25 2010-12-22 Genentech, Inc. Humanisierte ANTI-ERBB2-Antikörper und Behandlung mit ANTI-ERBB2-Antikörpern
EP1265635A1 (de) * 2000-03-22 2002-12-18 Glaxo Group Limited Arzneimittel bestehend aus einem zellzyklus-blockierenden mittel und einem antikörper
AU1091802A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
ATE446317T1 (de) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten

Also Published As

Publication number Publication date
AU2010203050C1 (en) 2012-11-08
AT413486B (de) 2006-03-15
CA2488885A1 (en) 2004-01-15
US20090181030A1 (en) 2009-07-16
AU2010203050B2 (en) 2012-06-07
JP2006510578A (ja) 2006-03-30
US7527789B2 (en) 2009-05-05
WO2004005349A3 (en) 2004-10-28
US20050226880A1 (en) 2005-10-13
AU2010203050A1 (en) 2010-08-12
EP1517922A2 (de) 2005-03-30
WO2004005349A2 (en) 2004-01-15
AU2003258498A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
DE602004014968D1 (de) Elektrostatisch rückgekoppelter kapazitiver beschleunigungsaufnehmer mit ausgeglichener gasdämpfung
ATE501174T1 (de) Antikörper gegen madcam
CY2015050I1 (el) Βελτιστοποιημενη εκφραση της hpv 45 l1 σε ζυμη
NO20043996L (no) Fremgangsmate for frembringelse av API'er
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE60333189D1 (de) Elektromagnetischer dämpfer
ATE471344T1 (de) Antikörper gegen vla-1
DE60326970D1 (de) Gegen gewebefaktor gerichtete antikörper als antikoagulantien
NO20044347L (no) Anti-alfavbeta6-antistoff
ATE464068T1 (de) Antikörper gegen opgl
DE60336123D1 (de) Heftinstrument
DE60306080D1 (de) Toner
DE60229509D1 (de) Anti-osteopontin-antikörper und dessen verwendung
ATE426616T1 (de) Antikírper gegen menschliches mcp-1
DE50303193D1 (de) Übertrager
DE60304985D1 (de) Toiletteneinheit eines Flugzeuges
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
DE60323487D1 (de) Elektromagnetischer dämpfer
ATA9952002A (de) Verwendung eines antikörpers gerichtet gegen lewis-antigene
DE602004030435D1 (de) Verwendung eines metallkatalysators
ITTO20020621A1 (it) Gruppo integrato puleggia-smorzatore torsionale
DE60316134D1 (de) Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
ATE394140T1 (de) Verwendung neuer etonogestrelester
DE502004000215D1 (de) Quasikristalline Ti-Cr-Al-Si-O Legierung und deren Verwendung als Beschichtungen

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
MM01 Lapse because of not paying annual fees

Effective date: 20160815